FBR Capital Initiates Regulus Therapeutics With Outperform

Analysts at FBR Capital initiated coverage on Regulus Therapeutics Inc (NASDAQ: RGLS) with a Outperform rating.

The target price for Regulus Therapeutics is set to $30.

Regulus Therapeutics shares have gained 133.42 percent over the past 52 weeks, while the S&P 500 index has surged 11.75 percent in the same period.

Regulus Therapeutics' shares fell 0.69 percent to close at $17.18 yesterday.